Real‐World Data on Prognostic Factors for Overall Survival in EGFR Mutation‐Positive Advanced Non‐Small Cell Lung Cancer Patients Treated with First‐Line Gefitinib

BACKGROUND. This study aimed to identify independent prognostic factors for overall survival (OS) of patients with advanced non‐small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation and receiving gefitinib as first‐line treatment in real‐world practi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Yao, Zong‐Han, Liao, Wei‐Yu, Ho, Chao‐Chi, Chen, Kuan‐Yu, Shih, Jin‐Yuan, Chen, Jin‐Shing, Lin, Zhong‐Zhe, Lin, Chia‐Chi, Chih‐Hsin Yang, James, Yu, Chong‐Jen
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Lung Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5599189/
https://ncbi.nlm.nih.gov/pubmed/28507206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0331
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados